- Ainos ( NASDAQ: AIMD ) has surged 50% premarket after the company said its low-dose oral interferon ( IFN )-alpha formulation Veldona showed a positive effect on lungs infected with the the Omicron variant of the coronavirus by regulating the immune response, thereby expediting recovery of hamsters.
- The copany had filed an application to the U.S. Food and Drug Administration (FDA) seeking clearance to conduct a phase 2 trial for the drug.
- The study tested the effectiveness of Veldona over a sixteen-day course and compared with hamsters in the placebo group. The hamsters in the group receiving Veldona showed resistance to body weight loss immediately after infection, then showed a better recovery trend in the following three days.
For further details see:
Ainos rises 50% on positive data from animal study trial of Veldona to treat COVID-19